Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Amgen (NQ: AMGN )

250.58 -2.57 (-1.02%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,882,197
Open 251.19
Bid (Size) 249.00 (1)
Ask (Size) 253.10 (1)
Prev. Close 253.15
Today's Range 249.75 - 252.65
52wk Range 198.64 - 258.45
Shares Outstanding N/A
Dividend Yield 2.81%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Apple, IBM Are CNBC 'Fast Money' Calls Of The Day
CNBC’s "Fast Money: Halftime Report" delivers market-moving news to investors. 
Via Benzinga
Amgen Moves to Dismiss Regeneron's Antitrust Case Regarding Cholesterol Drug
 
Via Benzinga

Performance

YTD
+10.54%
+10.54%
1 Month
+2.76%
+2.76%
3 Month
+2.13%
+2.13%
6 Month
+11.90%
+11.90%
1 Year
+8.44%
+8.44%

More News

Read More
75 Firms Going Ex-Dividend Next Week, Including Target, Amgen And Chevron
Via Talk Markets
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Senate Finance Committee Expands Amgen's Tax Probe: Report
Via Benzinga
Amgen's Return on Invested Capital Overview
Via Benzinga
Analyst Ratings for Amgen
Via Benzinga
Amgen Q2 Earnings and Revenues Beat Estimates
Via Talk Markets
3 Best Funds for Aggressive Investors
Via InvestorPlace
4 Index Funds to Buy and Hold Forever
Via InvestorPlace
This Is What Whales Are Betting On Amgen
Via Benzinga
Karuna Therapeutics To $276? Plus SVB Leerink Almost Doubles Price Target On This Stock
Via Benzinga
Amgen's Lumakras/Keytruda/Tecentriq Combo Data Flags Safety Concern
Via Benzinga
Two Appealing Biotech Stocks for Two Distinct investors
Via MarketBeat
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Small Cap Biotechs Perk Up On Dealmaking
Via Talk Markets
Amgen's Q2 Sales Impacted By Lower Prices, Currency Headwind, Reaffirms FY22 Outlook
Via Benzinga
What Are Whales Doing With Amgen
Via Benzinga
Stock Market Rally Mixed As Oil Prices Fall, Job Growth Hot: Weekly Review
Via Investor's Business Daily
Amgen Narrows Sales Outlook Following Plans To Acquire ChemoCentryx
Via Investor's Business Daily
Recap: Amgen Q2 Earnings
Via Benzinga
ChemoCentryx Shares Are Jumping 110% Thursday: Here's Why
Via Benzinga
ChemoCentryx (NASDAQ: CCXI) to be Acquired by Amgen (NASDAQ: AMGN) for $3.7 Billion in Cash
Via Spotlight Growth
ChemoCentryx (CCXI) Stock Soars 100% on Amgen Acquisition
Via InvestorPlace
Amgen Plans $3.7 Billion ChemoCentryx Buyout, Tapping Into A New Market
Via Investor's Business Daily
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.